Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02196714 · ClinicalTrials.gov registry record · Phase 1
PK Study of PT003 and PT001 in Japanese Healthy Subjects
A Phase 1 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02196714 is a Phase 1 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 24 participants.
The verdict
NCT02196714, a Phase 1 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Single-Dose, Four-Period, Four-Treatment, Cross-Over, Single-Center, Phase I, Crossover Study in Healthy Japanese Adult Subjects to Evaluate the Safety and Pharmacokinetics of Two Doses of PT003 and Two Doses of PT001.
Interventions
- DRUG Glycopyrronium and Formoterol Fumarate (GFF) Dose 1
- DRUG Glycopyrronium and Formoterol Fumarate (GFF) Dose 2
- DRUG Glycopyrronium (GP) Dose 1
- DRUG Glycopyrronium (GP) Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02196714
The ClinicalTrials.gov registry entry for NCT02196714 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Glycopyrronium and Formoterol Fumarate (GFF) Dose 1 is the first listed.
NCT02196714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02196714 about?
NCT02196714 is a clinical study titled "PK Study of PT003 and PT001 in Japanese Healthy Subjects". A Randomized, Double-Blind, Single-Dose, Four-Period, Four-Treatment, Cross-Over, Single-Center, Phase I, Crossover Study in Healthy Japanese Adult Subjects to Evaluate the Safety and Pharmacokinetics of Two Doses of PT003 and Two Doses of PT001.
What is the current status of trial NCT02196714?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-07.
What interventions are being tested in trial NCT02196714?
The interventions under investigation include: Glycopyrronium and Formoterol Fumarate (GFF) Dose 1 (DRUG), Glycopyrronium and Formoterol Fumarate (GFF) Dose 2 (DRUG), Glycopyrronium (GP) Dose 1 (DRUG), Glycopyrronium (GP) Dose 2 (DRUG).
Who is sponsoring clinical trial NCT02196714?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.